The EHMT1 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the EHMT1 gene in the human near-haploid HAP1 cell line. This heterogeneous pool provides a loss-of-function model for studying EHMT1-mediated epigenetic regulation without clonal isolation. The polyclonal format supports population-level assays and screens requiring biological variability, making it suitable for bulk analyses such as ChIP-qPCR and RNA-seq.
The HAP1 cell line is a near-haploid, adherent, fibroblast-like line derived from KBM-7 chronic myeloid leukemia (CML) cells. Its haploid karyotype simplifies knockout generation and phenotypic analysis by requiring disruption of a single allele. HAP1 retains key cancer signaling pathways and is widely used as a genetic screening tool, enabling CRISPR-based library screens and drug sensitivity assays. The robust growth and adherent morphology facilitate diverse experimental workflows.
EHMT1 (GLP) is a histone methyltransferase that catalyzes histone H3 lysine 9 monomethylation and dimethylation (H3K9me1/me2), marks associated with transcriptional repression. It functions as an obligate heterodimer with EHMT2 (G9a) in a complex that includes WIZ, CTBP, DNMT1, and UHRF1. Upstream regulators such as REST, E2F1, and ATF4 control EHMT1 activity, and DNA damage signaling enhances its repressive function. Downstream, EHMT1 silences target genes including CDKN1A, FOS, and CCND1 through H3K9 methylation and HP1 recruitment. This repressive network links EHMT1 to heterochromatin formation and tumor suppressor gene silencing, implicating it in oncogenesis and developmental disorders.
In the HAP1 background, EHMT1 disruption enables dissection of epigenetic contributions to leukemogenesis and cancer cell phenotypes. The haploid state ensures direct genotype-phenotype correlation, facilitating studies of dose-dependent epigenetic effects and synthetic lethality. This model is relevant for myeloid malignancies, breast cancer, and Kleefstra syndrome research. The HAP1 context allows co-analysis of EHMT1 with its partners EHMT2 and HP1 in a human cell system.
Typical applications of these polyclonal EHMT1 knockout cells include chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) to assess H3K9me1/me2 enrichment at target promoters, gene expression analysis by RT-qPCR or RNA-seq, and co-immunoprecipitation to study the EHMT1-EHMT2 complex. Western blotting can be employed to measure global H3K9 methylation changes. The cells are suitable for drug sensitivity assays using HDAC inhibitors or specific EHMT1/2 inhibitors, providing a platform for drug target validation. They also enable investigation of EHMT1 function in Wnt and Notch signaling pathways and in DNA damage responses. For further information, please contact Ascent Research.
